Lactobacillus acidophilus strain L.B (probiotic): benefits, dosage, contraindications
Scientific name(s)
Lactobacillus acidophilus
Family or group:
Probiotics
Indications
Scoring methodology
EFSA approval.
Helicobacter pylori infection ✪✪✪✪✪
The antimicrobial effect of L.B. actives observed on enteropathogens has been demonstrated against Helicobacter pylori, a pathogenic microorganism involved in stomach disorders. Indeed, in the presence of L.B. actives, "urease" activity, which is an essential pathogenicity factor for Helicobacter motility and its ability to colonize the mucosa, is strongly reduced.
Posologie
Orally
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates
Lactobacillus acidophilus LB: a useful pharmabiotic for the treatment of digestive disorders
Diarrhea ✪✪✪✪✪
L.B. actives have a clinically demonstrated antisecretory activity. Indeed, two randomized, double-blind, placebo-controlled clinical trials conducted in children with non-viral acute diarrhea showed a reduction in symptoms of about 40% in children who received L.B. actives compared with children who received a placebo.
Posologie
Orally
Effectiveness and safety of Lactobacillus LB in the treatment of mild acute diarrhea in children
Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children
An experimental study and a randomized, double-blind, placebo-controlled clinical trial to evaluate the antisecretory activity of Lactobacillus acidophilus strain LB against non-rotavirus diarrhea
Bacterial infections ✪✪✪✪✪
The L.B actives exert an antibacterial effect against Salmonella typhi by degrading membrane polysaccharides and increasing the permeability of the bacteria's outer membrane. The activity of the L.B actives is greater than or equal to that of the reference antibiotic (polymyxin) and cannot be attributed to lactic acid. Furthermore, the L.B actives have antimicrobial activity against many other potentially pathogenic organisms: Staphylococcus aureus, Listeria, Shigella, Escherichia coli, Klebsiella, Bacillus cereus, Pseudomonas aeruginosa, and Candida albicans.
Posologie
Orally
Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB
A gastrointestinal anti-infectious biotherapeutic agent: the heat-treated Lactobacillus LB
Antibacterial effect of the adhering human Lactobacillus acidophilus strain LB.
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates
Lactobacillus acidophilus LB: a useful pharmabiotic for the treatment of digestive disorders
Intestinal permeability ✪✪✪✪✪
Following injury from an infectious agent, stress, or repeated use of medications, the cells of the intestinal mucosa can be damaged. L.B. active ingredients accelerate the repair of the cellular skeleton (the actin protein network), and thus cell function, thereby helping to reduce intestinal hyperpermeability. This action is observed both in the intestine and in the stomach, to repair cellular lesions caused by Helicobacter pylori on the gastric mucosa.
Posologie
Oral administration
Lactobacillus acidophilus LB: a useful pharmabiotic for the treatment of digestive disorders
Effectiveness and safety of Lactobacillus LB in the treatment of mild acute diarrhea in children
An experimental study and a randomized, double-blind, placebo-controlled clinical trial to evaluate the antisecretory activity of Lactobacillus acidophilus strain LB against nonrotavirus diarrhea
Candidiasis ✪✪✪✪✪
Vulvovaginal candidiasis are very common fungal infections that affect a large proportion of women of childbearing age. The pathogen is generally Candida albicans, an opportunistic yeast that grows when the vaginal balance and local immune mechanisms are disrupted. Vaginal recolonization through the use of Lactobacillus acidophilus may restore vaginal pH and promote normal growth of the bacterial flora. In preventing recurrences, the benefit of using probiotics is debated. In vitro studies have shown that lactobacilli can inhibit the growth of Candida albicans and/or its adherence to the vaginal epithelium. Results from some clinical trials support the effectiveness of certain lactobacilli strains such as Lactobacillus acidophilus, Lactobacillus rhamnosus, and Lactobacillus fermentum, administered either orally or vaginally. A recent study further supports these conclusions by showing that adding lactobacilli would strengthen standard treatment with fluconazole.
Posologie
Orally
Properties
Antimicrobial
The L.B. strain has a strong ability to inhibit adhesion of enteropathogenic organisms. Indeed, it has antimicrobial activity against many organisms with pathogenic potential: Staphylococcus aureus, Listeria, Salmonella, Shigella, Escherichia coli, Klebsiella, Bacillus cereus, Pseudomonas aeruginosa and Candida albicans. rnrnThe antimicrobial effect of L.B. actives observed on enteropathogens has also been demonstrated against Helicobacter pylori, a pathogenic organism involved in stomach disorders. Indeed, in the presence of L.B. active compounds, the "urease" activity, which is an essential pathogenicity factor for Helicobacter motility and its ability to colonize the mucosa, is strongly reduced. rnrn
Usages associés
Gastroprotective
L.B. active compounds exert a protective effect on enterocyte junctions against alterations caused by certain medications. They reduce cell death and restore the natural barrier function of the mucosa. In addition, L.B. active compounds optimize the functionality of the digestive mucosa through an antisecretory activity. rnrn
Usages associés
Digestive effect
Following an assault by an infectious agent, stress, or repeated use of medications, the cells of the intestinal mucosa can be damaged. L.B. active compounds accelerate the repair of the cellular scaffold (the actin protein network), and thus cell functionality, contributing to the reduction of intestinal hyperpermeability. This action is observed both in the intestine and in the stomach, to repair the cellular lesions caused by Helicobacter pylori on the gastric mucosa. rnrn
Usages associés
Safe dosage
Child :
An analysis of 57 clinical trials showed that administration of probiotics and/or symbiotic organisms in immunocompromised adults (human immunodeficiency virus infection, patients with serious, surgical, or autoimmune disease) is safe. In particular, the safety of L. acidophilus LB has been demonstrated in two controlled clinical trials and no adverse effects were reported.
Adult :
A review of 57 clinical trials showed that the administration of probiotics and/or synbiotic organisms in immunocompromised adults (human immunodeficiency virus infection, patients with severe, surgical, or autoimmune disease) is safe. In particular, the safety of L. acidophilus LB was demonstrated in two controlled clinical trials and no adverse effects were reported.
